Clinical Trials Logo

Clinical Trial Summary

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies


Clinical Trial Description

This study includes a dose-escalation phase in Part A to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) followed by 6 monotherapy expansion arms in Part B to further evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of 23ME-00610 in patients with solid malignancies. Cohort 1B will enroll up to 15 evaluable patients with locally advanced (unresectable) or metastatic clear cell renal cell carcinoma (ccRCC). Cohort 2B will enroll up to 13 evaluable patients with locally advanced (unresectable) or metastatic epithelial ovarian, fallopian tube or primary peritoneal carcinoma of non clear-cell histology, and up to 2 evaluable patients with clear cell histology (up to 15 total). Cohort 3B will enroll up to 15 evaluable patients with locally advanced (unresectable) or metastatic neuroendocrine cancers. Cohort 4B will enroll up to 15 evaluable patients with locally advanced (unresectable) or metastatic microsatellite instability-high (MSI-H) and/or tumor mutational burden-high (TMB-H) solid cancers, including at least 10 evaluable MSI-H cancers. Cohort 5B will enroll up to 15 evaluable adolescent patients with locally advanced (unresectable), or metastatic solid cancers. Cohort 6B will enroll up to 15 evaluable patients with locally advanced (unresectable) or metastatic extensive stage small cell lung cancer (ES-SCLC). Up to 15 additional evaluable patients may be added to any disease-specific cohort in Part B to evaluate another dose level with pharmacologic or PD evidence of therapeutic effect below the MTD/RP2D identified in Part A (for a maximum of 30 patients in total at the alternate dose). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05199272
Study type Interventional
Source 23andMe, Inc.
Contact Study Inquiry
Phone (650) 963-8997
Email studyinquiry@23andme.com
Status Recruiting
Phase Phase 1/Phase 2
Start date December 29, 2021
Completion date June 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012 in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Not yet recruiting NCT05379946 - Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05046808 - Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects Phase 1